ArticleNature2021
A non-hallucinogenic psychedelic analogue with therapeutic potential.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 261 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
261citing papers in PubMed, 3 pooled it
19.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
261 citing papers in PubMed, 3 syntheses or guidelines pooled it, 444 citations in OpenAlex.
- Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature.Journal of psychopharmacology (Oxford, England) · 2026Pooled it
- Therapeutic Use of Psilocybin in Depression: a Systematic Review of Clinical Evidence.Acta neuropsychiatrica · 2025Pooled it
- Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature.Current neuropharmacology · 2023Pooled it
- Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.Journal of psychopharmacology (Oxford, England) · 2024Trial
- 5-HTNature neuroscience · 2026Article
- Ibogaine for Substance Use Disorders.Advances in therapy · 2026Review
- Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Article
- Deconstruction of lysergic acid diethylamide.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Ibogalogs reduce acute and chronic headache-like behaviours in rodents by different co-modulatory mechanisms involving 5-HTResearch square · 2026Article
- Mechanistic Basis for 5-HTNature communications · 2026Article
- The Emergence of Isotryptamine Analogs as Novel Serotonergic Agents with Psychotherapeutic Potential.ACS pharmacology & translational science · 2026Review
- Psychedelic 4-AcO-DMT attenuated looming-induced freezing behaviors by activating PrLMolecular psychiatry · 2026Article
- Psilocybin enhances sociability only in altered behavioural state and does not need an awake experience to be effective.Nature communications · 2026Article
- Inhalable Psychedelic 5-MeO-DMT Shows Promise in Treatment-Resistant Depression.Journal of medicinal chemistry · 2026Article
- Multibehavioral Phenotyping in Early-Life-Stage Zebrafish for Identifying Disruptors of Nonassociative Learning.Environmental health perspectives · 2026Article
- Classic Psychedelics for Treating Chronic Pain: Mechanism and Clinical Translation.Molecules (Basel, Switzerland) · 2026Review
- Psychedelic drug action at dendrites is gated by behavioral state and serotonin receptors.bioRxiv : the preprint server for biology · 2026Article
- Dissociating the Hallucinogenic and Neuroplastic Effects of Psilocybin.bioRxiv : the preprint server for biology · 2026Article
- The working lives of neuronal 5-HTRSC chemical biology · 2026Review
201 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
29 authors at 7 institutions in 1 country.
Lindsay P CameronNeuroscience Graduate Program, University of California, Davis, Davis, CA, USA.ORCID http://orcid.org/0000-0002-8420-7898
Robert J TombariDepartment of Chemistry, University of California, Davis, Davis, CA, USA.ORCID http://orcid.org/0000-0002-6561-8181
Ju LuDepartment of Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, CA, USA.
Alexander J PellDepartment of Chemistry, University of California, Davis, Davis, CA, USA.ORCID http://orcid.org/0000-0003-4463-4761
Zefan Q HurleyDepartment of Chemistry, University of California, Davis, Davis, CA, USA.
Yann EhingerDepartment of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Maxemiliano V VargasNeuroscience Graduate Program, University of California, Davis, Davis, CA, USA.
Matthew N McCarrollInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA.
Jack C TaylorInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-6431-9956
Douglas Myers-TurnbullInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA.
Taohui LiuDepartment of Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, CA, USA.
Bianca YaghoobiDepartment of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, Davis, CA, USA.
Lauren J LaskowskiDepartment of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI, USA.
Emilie I AndersonDepartment of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI, USA.
Guoliang ZhangDepartment of Chemistry, University of California, Davis, Davis, CA, USA.
Jayashri ViswanathanDepartment of Chemistry, University of California, Davis, Davis, CA, USA.ORCID http://orcid.org/0000-0002-1293-827X
Brandon M BrownDepartment of Pharmacology, School of Medicine, University of California, Davis, Davis, CA, USA.
Michelle TjiaDepartment of Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, CA, USA.
Lee E DunlapDepartment of Chemistry, University of California, Davis, Davis, CA, USA.
Zachary T RabowWest Coast Metabolomics Center, University of California, Davis, Davis, CA, USA.ORCID http://orcid.org/0000-0001-6213-4950
Oliver FiehnWest Coast Metabolomics Center, University of California, Davis, Davis, CA, USA.ORCID http://orcid.org/0000-0002-6261-8928
Heike WulffDepartment of Pharmacology, School of Medicine, University of California, Davis, Davis, CA, USA.ORCID http://orcid.org/0000-0003-4437-5763
John D McCorvyDepartment of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID http://orcid.org/0000-0001-7555-9413
Pamela J LeinDepartment of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, Davis, CA, USA.ORCID http://orcid.org/0000-0001-7665-7584
David KokelInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA.
Dorit RonDepartment of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Jamie PetersDepartment of Anesthesiology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.ORCID http://orcid.org/0000-0002-7573-6384
Yi ZuoDepartment of Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, CA, USA.ORCID http://orcid.org/0000-0001-9020-0003
David E OlsonDepartment of Chemistry, University of California, Davis, Davis, CA, USA. deolson@ucdavis.edu.ORCID http://orcid.org/0000-0002-4517-0543
University of California, Davis · USUniversity of California, San Francisco · USUniversity of California, Santa Cruz · USMedical College of Wisconsin · USQB3 · USSilence Therapeutics (United States) · USUniversity of Colorado Anschutz Medical Campus · US
Funding
Systems BiologyU19AG023122 · NIA · TRANSLATIONAL GENOMICS RESEARCH INST · PI PAOLA SEBASTIANI · 2004 to 2026
$102.6MUC Davis Clinical and Translational Science CenterUL1TR001860 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J., LYLES, COURTNEY REES · 2016 to 2025
$47.3MWISCONSIN CENTER ON MENTAL RETARDATION: CORE SUPPORTP30HD003352 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI DAVIDSON, RICHARD J · 1985 to 2015
$25.2MResearch Project: Pathologic Significance of Maternal AutoantibodiesP50HD103526 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEONARD J. ABBEDUTO, Melissa Dawn Bauman · 2020 to 2026
$9.7MRodent Behavior CoreU54HD079125 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ABBEDUTO, LEONARD J. · 2013 to 2019
$8.5MUC Davis CTSC TL1 Administrative Supplement to Recognize Excellence in Diversity, Equity, Inclusion, and Accessibility MentorshipTL1TR001861 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MEDICI, VALENTINA · 2016 to 2025
$4.7MBDNF and Alcohol AddictionR37AA016848 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RON, DORIT · 2013 to 2022
$3.7MIntegrative Omics to enhance therapeutics development for healthy agingUH3AG064706 · NIA · TRANSLATIONAL GENOMICS RESEARCH INST · PI MILLER, RICHARD A, SCHORK, NICHOLAS JOSEPH · 2021 to 2024
$3.3MImpact of sleep-wake circuits on cortical synapse plasticity during motor learningR01NS104950 · NINDS · STANFORD UNIVERSITY · PI MOURRAIN, PHILIPPE · 2018 to 2022
$2.6MLearning, Memory, and Plasticity (LaMP) Training ProgramT32MH112507 · NIMH · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Karen Zito · 2017 to 2026
$2.4MPredoctoral Training in Pharmacological SciencesT32GM099608 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HELL, JOHANNES W · 2012 to 2021
$2.2MDynamics and molecular mechanism of synaptic connectivity change during learningR01MH104227 · NIMH · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI ZUO, YI · 2014 to 2018
$2.1MNCATS NIH HHS TL1 TR001861NCATS NIH HHS UL1 TR001860NCRR NIH HHS S10 RR019266NIAAA NIH HHS R01 AA022583NIAAA NIH HHS R37 AA016848NIA NIH HHS U19 AG023122NIA NIH HHS UH3 AG064706NICHD NIH HHS P30 HD003352NICHD NIH HHS P50 HD103526NICHD NIH HHS U54 HD079125NIDA NIH HHS R01 DA045836NIGMS NIH HHS R01 GM128997NIGMS NIH HHS T32 GM099608NIGMS NIH HHS T32 GM113770NIH HHS 1S10 RR019266-01NIH HHS 4T32 GM6754714NIH HHS 5T32 GM099608NIH HHS R37 AA01684NIMH NIH HHS R01 MH104227NIMH NIH HHS R01 MH109475NIMH NIH HHS T32 MH112507NINDS NIH HHS R01 NS104950
Abstract
The psychedelic alkaloid ibogaine has anti-addictive properties in both humans and animals
Indexed as
Drug DesignAlcoholismAnimalsAntidepressive AgentsArrhythmias, CardiacBehavior, AddictiveChemistry Techniques, SyntheticDepressionDisease Models, AnimalFemaleHallucinogensHeroin DependenceIbogaineMaleMiceMice, Inbred C57BLAntidepressive AgentsHallucinogensIbogaineReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor Agonists
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.